Microbix upgraded logistics software systems achieves “Go-Live” with ERP and eQMS solutions
by CM staff
Microbix announced its selection of new ERP and eQMS systems in March, 2022, with its goal being to achieve “Go-Live” with each by the end of fiscal 2023.
MISSISSAUGA — Microbix Biosystems Inc., a life sciences manufacturer, and exporter, announces its successful adoption of software to upgrade, digitize, and integrate its Enterprise Resource Planning (ERP) platform and electronic Quality Management System (eQMS).
These logistics IT systems are intended to facilitate growth in sales of Microbix’s product lines and thereby enable achievement of its business objectives.
Microbix announced its selection of new ERP and eQMS systems in March, 2022, with its goal being to achieve “Go-Live” with each by the end of fiscal 2023 (i.e., September 30, 2023).
That goal is now achieved, with the new ERP software supporting operations from raw materials procurement through to receivables collection. In turn, processes relating to product development, SKU manufacturing, QC/QA, and staff training are now being digitized via the new eQMS system.
These logistics software upgrades are deemed essential for Microbix to realize its objective of driving sales toward C$100 million per year while maintaining quality and pricing.
NetSuite® is Microbix’s chosen ERP software, approaching 30,000 clients with over 1,000 in the Medtech/Pharma fields. This ERP integrates with eQMS to provide a scalable solution including manufacturing, QC/QA, finance, sales & CRM, inventory control, and compliance.
“Over the past few years we’ve effectively doubled sales and also increased our number of SKUs,” said Jim Currie, Microbix’s Chief Financial Officer commented. “The growing scale and complexity of Microbix has made it critical that our ERP supports all our transactional, reporting, and analytical needs. We’re now pleased to be actively using both new software systems to support Microbix’s daily operations.”
Since the announcement of these projects in spring of 2022, Microbix has invested an estimated C$0.8 million in subscription fees and implementation costs, approximately 75 per cent of which has been absorbed in fiscal 2023.
These projects have been supported in part by grants from the Ontario Together Fund of the Government of Ontario and loans from the FedDev Ontario program of the Government of Canada.
